FNAM (Evolutionary Genomics) Debt-to-EBITDA : -5.96 (As of Dec. 2022)

What is Evolutionary Genomics Debt-to-EBITDA?

Evolutionary Genomics FNAM 31 Debt-to-EBITDA is -5.96 as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evolutionary Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Evolutionary Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $3.74 Mil. Evolutionary Genomics's annualized EBITDA for the quarter that ended in Dec. 2022 was $-0.63 Mil. Evolutionary Genomics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was -5.96.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Evolutionary Genomics's Debt-to-EBITDA or its related term are showing as below:

FNAM's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.14
* Ranked among companies with meaningful Debt-to-EBITDA only.

Evolutionary Genomics (OTCPK:FNAM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Evolutionary Genomics Debt-to-EBITDA Related Terms

Evolutionary Genomics Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Debt-to-EBITDA Chart

Evolutionary Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

Get a 7-Day Free Trial

0.00

-0.91

-2.04

-3.77

Evolutionary Genomics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-EBITDA	Get a 7-Day Free Trial															-2.29	-3.47	-3.39	-3.23	-5.96

FNAM vs BXRX, GNCA, XSNX: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Evolutionary Genomics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolutionary Genomics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Debt-to-EBITDA falls into.

Save Embed

31GF Score

Evolutionary Genomics Inc FNAM

Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Evolutionary Genomics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evolutionary Genomics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	3.744)	/	-0.993
	=	-3.77

Evolutionary Genomics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	3.744)	/	-0.628
	=	-5.96

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2022) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of -5.96 mean?

Evolutionary Genomics (FNAM) has a Debt-to-EBITDA of -5.96 as of Dec. 2022. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evolutionary Genomics.

Is Evolutionary Genomics' Debt-to-EBITDA too high?

Evolutionary Genomics' current Debt-to-EBITDA is -5.96. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Evolutionary Genomics' Debt-to-EBITDA compare to BXRX and GNCA?

Evolutionary Genomics' Debt-to-EBITDA of -5.96 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Biotechnology company?

The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evolutionary Genomics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolutionary Genomics's current Debt-to-EBITDA is -5.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evolutionary Genomics stock overvalued right now?

Evolutionary Genomics (FNAM) has a current Debt-to-EBITDA of -5.96. The current Debt-to-EBITDA is -5.96. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Debt-to-EBITDA is -5.96 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Industry Healthcare Biotechnology

Comparable Companies BXRX GNCA XSNX KPRX HCYT EVFM KRBP TTNP ATXI ISCO OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

31GF Score

Get the complete analysis for FNAM

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View FNAM Analysis

See Debt-to-EBITDA data for all stocks →